Arch Bio Completes Pre-IND Meeting with FDA on LSALT

June 19, 2019 - Market Doesn't React

Arch Announces Start of Phase I

Aug 22, 2019 - Market Doesn't React

Third Party Validation of Mechanism of Action

March 17, 2020 - Market Doesn't React

Arch Expands Phase I Trial

May 8, 2020 - Market Reacts .90-1.20

Arch Receives Health Canada Approval for Phase II

June 16, 2020 - Market Reacts 1.40-1.65

Arch Recieves FDA Approval for Phase II

Dec 15, 2020 - Market Doesn't React 

Arch Announces Phase II Government Funding

Feb 2, 2021 - Market Doesn't React

Arch Receives Ethics Committee Approval in Turkey to Dose Additional Patients

Feb 26, 2021 - Market Doesn't React

Arch Expands Phase II to additional Calgary Hospital

March 16, 2021 - Market Doesn't React

Arch Receives Health Canada Authorization to Amend Phase II

April 15, 2021 - Market Doesn't React

Arch Enters Worldwide License Agreement to Re-Purpose Cilistatin for the Treatment and Prevention of Acute Kidney Injury - Opportunity for a NEW Phase II Trial for MetaBlok and Cilastatin Targeting AKI

May 4, 2021 - Market Doesn't React

Arch Completes Enrollment in Phase II

June 10, 2021 - Market Doesn't React

Arch Files New Patent Application For Novel Antibody CANDIDATES Targeting DPEP-1 Mediated Organ Inflammation

July 14, 2021 - Market Doesn't React

Arch Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

Aug 5, 2021 - Market Doesn't React

Arch Provides Update on Phase II - Sends Data For Third Party Validation

Dec 1, 2021 - Market Doesn't React $5.04

Arch to Enter CATCO(Phase III) - Funded by CIHR - Drug in hand

Share Structure:
 
  • The Company had 47,360,179 Common Shares outstanding as of May 7, 2010. As of the date hereinabove, the Company has 61,862,302 common shares outstanding.
  • No warrants outstanding